LOTTE Biologics to Showcase Global CDMO Competitiveness 

at Major Biopharma Events

 

▲ [Photo] LOTTE Biologics’ exhibition booth at the CPHI Milan 2026 in Milan, Italy
 

Seoul, South Korea, September 14, 2026 — LOTTE Biologics (co-CEOs James Park and Yoo-yeol Shin), announced that it will participate in a series of major global biopharmaceutical conferences throughout October to showcase its capabilities as a global contract development and manufacturing organization (CDMO).

LOTTE Biologics will host dedicated exhibition booths at CPHI Milan 2026, taking place in Milan, Italy, from October 6 to 8, and Bio Japan 2026, to be held in Yokohama, Japan, from October 7 to 9. The company will also participate in World ADC San Diego, taking place in San Diego, California, from October 12 to 15.

Through its presence at these major industry events, LOTTE Biologics plans to strengthen partnerships with pharmaceutical and biotechnology companies worldwide while actively exploring new business opportunities.

CPHI Milan 2026, one of the world’s largest pharmaceutical and biopharmaceutical exhibitions, is held annually in major European cities. At its dedicated booth, LOTTE Biologics will highlight its large-scale commercial manufacturing capabilities ahead of GMP readiness at the Songdo Bio Campus, as well as the competitive advantages of its dual-site network spanning Korea and the U.S.

On the first two days of the event, the company will host in-booth presentations highlighting its large-scale commercial manufacturing capabilities and expertise in bispecific antibodies. LOTTE Biologics will also focus on partnering activities, conducting business meetings with prospective clients and partners in private meeting rooms of various sizes.

At its dedicated booth at Bio Japan 2026, LOTTE Biologics will showcase how technologies including its manufacturing control system (MCS), digital twin and computational fluid dynamics (CFD) simulations support manufacturing consistency and operational efficiency. The company will also hold partnering meetings with prospective global clients.

World ADC San Diego is a leading global event dedicated to antibody-drug conjugates (ADCs), bringing together pharmaceutical and biotechnology companies and industry experts to exchange the latest research findings and technology trends. During a presentation session, LOTTE Biologics will highlight the strengths of its proprietary ADC platform and demonstrate its technical competitiveness as an established global ADC CDMO.

Since the beginning of this year, LOTTE Biologics has continued to expand collaborations with global pharmaceutical and biotechnology companies, announcing four new contract awards to date. In June, the company also received approval for the use of Plant 1 at its Songdo Bio Campus, which is designed for large-scale manufacturing, further advancing its dual-site strategy connecting North America and Asia.

A LOTTE Biologics representative said, “As we approach GMP readiness at the Songdo Bio Campus, we are focused on showcasing our large-scale commercial manufacturing capabilities and the competitive advantages of our Korea-U.S. dual-site network to prospective clients worldwide. We will continue to expand global partnerships, secure new business opportunities and strengthen our competitiveness as a global CDMO.”